Grifols S.A. and Cerus Corporation agree to commercialize the INTERCEPT Blood System in Spain and Portugal

Both companies are dedicated to establishing a higher standard for the safety of Spanish and Portuguese blood transfusions

Barcelona, Spain July 23, 2007 – Grifols S.A. (MCE: GRF) and Cerus Corporation (NASDAQ: CERS) today announced that the two companies have entered into an agreement to commercialize Cerus’ INTERCEPT Blood System in Spain and Portugal. The INTERCEPT Blood System is designed to provide increased protection from a broad range of transfusion-transmitted pathogens. More than 200,000 platelet units and 300,000 plasma units for transfusion are collected annually in Spain and Portugal.

Under terms of the agreement, Grifols and Cerus will sell, deploy and support the INTERCEPT Blood System in Spanish and Portuguese blood centers. In addition, Grifols will be responsible for servicing the INTERCEPT system illuminators and will manage the supply chain for the INTERCEPT system through its distribution sites in Spain and Portugal.

“We are pleased to partner with Grifols, one of the largest pharmaceutical companies in Spain and the largest European plasma fractionator,” said Claes Glassell, president and chief executive officer of Cerus Corporation. “The two companies are committed to enhancing the safety of the blood supply in Spain and Portugal by using the most advanced technology to reduce the risk of transfusion-transmitted diseases.”

The INTERCEPT Blood System

The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens, such as viruses, bacteria, and parasites that may be present in donated blood intended for transfusion. The system inactivates pathogens in platelets and plasma using the same illumination device, process and active compound. The INTERCEPT Blood System has received CE mark approvals in Europe for both the platelet and plasma systems. A Phase I clinical trial of the INTERCEPT Blood System for red cells has been completed in the United States.
**About Cerus**

Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy designed to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company’s proprietary Helinx technology. The system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in the research and development of prophylactic and therapeutic vaccines for infectious diseases.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

**About Grifols**

Grifols is a Spanish holding company specialized in the hospital pharmaceutical sector. Currently present in 90 countries, it is the leading European company in the hemoderivative market and the fourth largest producer in the world. In the coming years Grifols will strengthen its leadership position in the industry as a vertically integrated company, as a results of investments already undertaken. Grifols has a steady and assured supply of plasma and its fractionation capacity will allow the company to meet growing demand, principally in the United States market where the company intends to increase its presence.

Grifols’ activities focus on fulfilling the needs of healthcare professionals working in therapeutics, pharmacy, diagnostics and blood banking. For more than 60 years Grifols has developed, manufactured and marketed products of proven efficacy, quality and safety contributing to improve human health.